Prevalence of Anti-SARS-CoV-2 Antibodies and Associated Factors Among Health Care Workers in Santiago De Cali, Colombia

References

• Manrique-Abril FG, Agudelo-Calderon CA, González-Chordá VM, Gutiérrez-Lesmes O, Téllez-Piñerez CF, Herrera-Amaya G. Modelo SIR de la pandemia de Covid-19 en Colombia. Rev Salud Publica. 2020;22(2):123–131. doi:10.15446/rsap.v22n2.85977
   Google Scholar
• Rojas-Botero M, Fernández-Niño JA, Ruiz-Gómez F. About the “critical reflections” on the municipal epidemiological resilience index. Rev Fac Med. 2021;69(3):e96924. doi:10.15446/revfacmed.v69n3.96924
   Google Scholar
• Sethuraman N, Jeremiah SS, Ryo A. interpreting diagnostic tests for SARS- CoV-2. JAMA. 2020;323(22):2249–2251. doi:10.1001/jama.2020.8259
   PubMed Web of Science ®Google Scholar
• Instituto Nacional de Salud de Colombia y Grupo Colaborativo Estudio País. Seroprevalencia de SARS-CoV-2 durante la epidemia en Colombia: estudio país [National Institute of Health of Colombia and Country Study Collaborative Group. SARS-CoV-2 seroprevalence during the epidemic in Colombia: country study; 2020]; 2020 Available from: https://www.ins.gov.co/BibliotecaDigital/Seroprevalencia-Colombia-reporte-preliminar-n-2.pdf. Accessed February 14, 2023.
   Google Scholar
• Palmateer NE, Dickson E, Furrie E, et al. National population prevalence of antibodies to SARS-CoV-2 in Scotland during the first and second waves of the COVID-19 pandemic. Public Health. 2021;198:102–105. doi:10.1016/j.puhe.2021.07.006
   PubMed Web of Science ®Google Scholar
• Rostami A, Sepidarkish M, Fazlzadeh A, et al. Update on SARS-CoV-2 seroprevalence: regional and worldwide. Clin Microbiol Infect. 2021;27(12):1762–1771. doi:10.1016/j.cmi.2021.09.019
   PubMed Web of Science ®Google Scholar
• Biebele J, Silkaitis C, Dolgin G, Bolon M, JaneCullen ZT. Occupational COVID-19 exposures and secondary cases among healthcare personnel. Am J Infect Control. 2021;49(10):1334–1336. doi:10.1016/j.ajic.2021.07.021
   PubMed Web of Science ®Google Scholar
• Carlsten C, Gulati M, Hines S, et al. COVID-19 as an occupational disease. Am J Ind Med. 2021;64(4):227–237. doi:10.1002/ajim.23222
   PubMed Web of Science ®Google Scholar
• Paduano S, Galante P, Berselli N, et al. Seroprevalence survey of anti-SARS-CoV-2 antibodies in a population of EmiliaRomagna Region, Northern Italy. Int J Environ Res Public Health. 2022;19(13):7882. doi:10.3390/ijerph19137882
   PubMed Web of Science ®Google Scholar
• Lai CC, Wang JH, Hsueh PR. Population-based seroprevalence surveys of anti-SARS-CoV-2 antibody: an up-to-date review. Int J Infect Dis. 2020;101:314–322. doi:10.1016/j.ijid.2020.10.011
   PubMed Web of Science ®Google Scholar
• Modenese A, Mazzoli T, Berselli N, et al. Frequency of anti-SARS-CoV-2 antibodies in various occupational sectors in an industrialized area of Northern Italy from May to October 2020. Int J Environ Res Public Health. 2021;18(15):7948. doi:10.3390/ijerph18157948
   PubMed Web of Science ®Google Scholar
• Phillips N. The coronavirus is here to stay - here’s what that means. Nature. 2021;590(7846):382–384. doi:10.1038/d41586-021-00396-2
   PubMed Web of Science ®Google Scholar
• Asplund K, Hermerén G. The need to revise the HELSINKI DECLARATION. Lancet. 2017;389(10075):1190–1191. doi:10.1016/S0140-6736(17)30776-6
   PubMed Web of Science ®Google Scholar
• Lopera MM. Commented review of the Colombian legislation regarding the ethics of health research. Biomédica. 2017;37(4):577–589. doi:10.7705/biomedica.v37i4.3333
   PubMed Web of Science ®Google Scholar
• Ariza B, Torres X, Salgado D, et al. Seroprevalence and seroconversion rates to SARS-CoV-2 in interns, residents, and medical doctors in a University Hospital in Bogotá, Colombia. Infectio. 2021;25(3):145–152. doi:10.22354/in.v25i3.938
   Google Scholar
• Herrera-Ortiz A, Rojas-Delgado HU, García-Cisneros S, et al. Prevalence of anti-SARS-CoV-2 antibodies and associated factors in healthcare workers of a Mexican Covid-19 hospital. Salud Publica Mex. 2022;64(4):348–356. doi:10.21149/13677
   PubMed Web of Science ®Google Scholar
• Poustchi H, Darvishian M, Mohammadi Z, et al. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study. Lancet Infect Dis. 2021;21(4):473–481. doi:10.1016/S1473-3099(20)30858-6
   PubMedGoogle Scholar
• Xu X, Sun J, Nie S, et al. Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China. Nat Med. 2020;26(8):1193–1195. doi:10.1038/s41591-020-0949-6
   PubMed Web of Science ®Google Scholar
• Garcia-Basteiro AL, Moncunill G, Tortajada M, et al. Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital. Nat Commun. 2020;11(1):3500. doi:10.1038/s41467-020-17318-x
   PubMed Web of Science ®Google Scholar
• Thomas SN, Altawallbeh G, Zaun CP, et al. Initial determination of COVID-19 seroprevalence among outpatients and healthcare workers in Minnesota using a novel SARS-CoV-2 total antibody ELISA. Clin Biochem. 2021;90:15–22. doi:10.1016/j.clinbiochem.2021.01.010
   PubMed Web of Science ®Google Scholar
• Korth J, Wilde B, Dolff S, et al. SARS- CoV-2-specific antibody detection in healthcare workers in Germany with direct contact to COVID-19 patients. J Clin Virol. 2020;128:104437. doi:10.1016/j.jcv.2020.104437
   PubMed Web of Science ®Google Scholar
• Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the diamond princess cruise ship, Yokohama, Japan, 2020. Euro Surveill. 2020;25(10):2000180. doi:10.2807/1560-7917.ES.2020.25.10.2000180
   PubMedGoogle Scholar
• Long QX, Tang XJ, Shi QL, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26(8):1200–1204. doi:10.1038/s41591-020-0965-6
   PubMed Web of Science ®Google Scholar
• Al-Qahtani M, AlAli S, AbdulRahman A, Salman Alsayyad A, Otoom S, Atkin SL. The prevalence of asymptomatic and symptomatic COVID-19 in a cohort of quarantined subjects. Int J Infect Dis. 2021;102:285–288. doi:10.1016/j.ijid.2020.10.091
   PubMed Web of Science ®Google Scholar
• Lesmes Rodríguez LC, Velandia-Bobadilla DJ, Jaramillo-Hernández DA. Seroincidencia de anticuerpos IgG del SARS-CoV-2 y factores de riesgo en trabajadores sanitarios asintomáticos del Hospital Departamental de Villavicencio. Rev Fac Nac Salud Pública. 2022;40(2):e346034. doi:10.17533/udea.rfnsp.e346034
   Google Scholar
• Xie J, Ding C, Li J, et al. Characteristics of patients with coronavirus disease (COVID-19) confirmed using an IgM-IgG antibody test. J Med Virol. 2020;92(10):2004–2010. doi:10.1002/jmv.25930
   PubMed Web of Science ®Google Scholar
• Lustig Y, Sapir E, Regev-Yochay G, et al. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. Lancet Respir Med. 2021;9(9):999–1009. doi:10.1016/S2213-2600(21)00220-4
   PubMed Web of Science ®Google Scholar
• Gilbert PB, Montefiori DC, McDermott AB, et al; Immune Assays Team; Moderna, Inc. Team; Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy (COVE) Team; United States Government (USG)/CoVPN Biostatistics Team. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022;375(6576):43–50. doi:10.1126/science.abm3425
   PubMed Web of Science ®Google Scholar
• Alejo JL, Mitchell J, Chang A, et al. Prevalence and durability of SARS-CoV-2 antibodies among unvaccinated US adults by history of COVID-19. JAMA. 2022;327(11):1085–1087. doi:10.1001/jama.2022.1393
   PubMed Web of Science ®Google Scholar